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Available online 7 September 2013Abstract Although recent findings showed that the bioactive lipid metabolites can regulate the ES cell functions, the
physiological relevance of interaction between sphingosine-1-phosphate (S1P) and Flk-1 and its related signaling molecules are
not yet clear in ES cell proliferation. In the present study, S1P1–5 receptors were expressed in mouse ES cells and S1P increased
S1P1–3 receptor expression level. S1P treatment stimulated the cellular proliferation in S1P1/3-dependent manner, located in
lipid rafts. In response to S1P, β-arrestin was recruited to S1P1/3 receptor and c-Src was activated. S1P also increased the
binding of S1P1/3 receptor with Flk-1. Similar to responses for VEGF, S1P increased Flk-1 phosphorylation, which was blocked by
β-arrestin siRNA, and PP2, but not by VEGF-A164 antibody or VEGF siRNA. In addition, S1P induced VEGF expression and VEGFR2
kinase inhibitor (SU1498) blocked the S1P-induced cellular proliferation. However, VEGF-A164 antibody or VEGF siRNA partially
blocked S1P-induced cellular proliferation, suggesting that both VEGF-dependent Flk-1 activation and VEGF-independent Flk-1
activation are involved in S1P-induced ES cell proliferation. S1P and VEGF-induced phosphorylation of ERK and JNK wereAbbreviations: ESC, Embryonic stem cell; S1P, Sphingosine-1-phosphate; Flk-1, Fetal Liver Kinase 1; VEGF, Vascular endothelial growth
factor; ERK, Extracellular signal-regulated kinases; JNK, c-Jun N-terminal kinases; RTK, Receptor tyrosine kinase; CDK, Cyclin dependent
kinase; MβCD, Methyl-β-cyclodextrin; CLM, Cholesterol-loaded MβCD.
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70 J.M. Ryu et al.blocked by pretreatment with SU1498. Moreover, inhibition of ERK and JNK blocked S1P-induced cellular proliferation. In
conclusion, S1P-elicited transactivation of Flk-1 mediated by S1P1/3-dependent β-arrestin/c-Src pathways stimulated mouse ES
cell proliferation.
© 2013 The Authors. Published by Elsevier B.V. Open access under the CC BY-NC-ND license.Introduction
A growing number of reports clearly demonstrate that the
lysophospholipid signaling mediators are critical regulators
of development, differentiation, migration and proliferation
of adult stem cells as well as embryonic stem (ES) cells
(Donati et al., 2007; Inniss and Moore, 2006; Kleger et al.,
2007; Seitz et al., 2005). Among the lysophospholipids,
sphingosine-1 phosphate (S1P) has attracted a great amount
of attention because it exerts various beneficial effects
such as promotion of migration, proliferation and protection
of apoptosis that are needed for therapeutic application of
stem cells (Pebay et al., 2005; Wong et al., 2007). S1P is
produced either by sphingosine kinases (SphK1 and SphK2)
involved in the metabolism of sphingomyelin, a component
of the plasma membrane (Spiegel and Milstien, 2007), or by
de novo synthesis (Hannun and Obeid, 2008). In a previous
report, genetic deletion of both SphK1 and SphK2 in mice
led to embryonic lethality before day 13.5 (Mizugishi et al.,
2005), thereby suggesting that the S1P is essential for early
embryonic development. Most of the S1P actions are medi-
ated by a family of G protein-coupled receptors, S1P1–5
(Spiegel and Milstien, 2003), allowing them to mediate many
different biological responses (Chun and Rosen, 2006; Rosen
and Goetzl, 2005). Similar to SphK knockout mice, S1P
receptor knockout mice die between E12.5 and E14.5 due to
severe developmental defects (Liu et al., 2000). In addition,
it has been reported that S1P has biphasic effects in the
regulation of differentiation and proliferation in various cell
types (Meyer zu Heringdorf and Jakobs, 2007; Niedernberg
et al., 2003; Wang et al., 2005), which may be explained by
differences in concentration and period of stimulation as
well as distribution and expression levels of S1P receptors
depending on the specific cell type. This suggests that the
fundamental differences in signaling and function of S1P are
due to the variation in coupling of the S1P receptors to the
G protein and the differences in cell type. It is therefore
important to elucidate the roles and its related signaling
mechanisms of S1P for proliferation of ES cells. On the other
hand, several investigations have suggested an interaction
between S1P receptors and receptor tyrosine kinases (RTKs)
as well as crosstalk between the activated signaling path-
ways that have been implicated in growth, survival, and
migration of mammalian cells (El-Shewy et al., 2006; Kim
et al., 2000; Pebay et al., 2005; Waters et al., 2003).
Interestingly, VEGF and its receptor are expressed in some
type of stem cells; opening the possibility that crosstalk
between S1P and VEGF signaling may be of importance
for self-renewal by regulating the survival, proliferation,
and migration of the stem cells (Atari et al., 2011; Lee et al.,
2009; Xiao et al., 2007). However, the physiological rele-
vance of these observations is not yet clear in ES cells and
little is known about the interaction of S1P and VEGF in
defined modulation of ES cell proliferation.ES cells, which have been used frequently for research
in the field of developmental biology and tried to apply
in cell-based regenerative medicine (Murry and Keller,
2008), replicate by the process of self-renewal and several
different pathways are believed to be involved in the
regulation of self-renewal, although the exact mechanisms
remain poorly understood (Avery et al., 2006; Niwa, 2001).
Although several studies with regard to this matter have
detailed on peculiar in vitro culture protocols for ES cells,
with the main effort being to optimize ES cell functions,
it is still important to develop defined culture systems
for expansion of ES cells in vitro in chemically-defined and
animal product-free conditions. Recent findings (Kleger et
al., 2007; Rodgers et al., 2009; Schuck et al., 2003) which
showed that the bioactive lipid metabolites can regulate
the ES cell functions have compelled us to investigate the
mechanism by which S1P regulates ES cell proliferation.
Thus, in this study, we examined the interaction between
both S1P and Flk-1 in regulation of ES cell proliferation and
its related signaling molecules.
Materials and methods
Materials
Mouse ES cell lines ES-E14TG2a and ES-R1 were obtained
from the American Type Culture Collection (Manassas, VA).
Both ES-E14TG2a and ES-R1 are pluripotent mouse embry-
onic stem cells. In the present study, ES-E14TG2a cells
were primarily used, and ES-R1 cells were used to examine
whether the responses observed in ES-E14TG2a cells de-
pended on cell type. Fetal bovine serum (FBS) was purchased
from BioWhittaker (Walkersville, MD, USA). Sphingosine-
1-phosphate (S1P), methyl-β-cyclodextrin (MβCD), JTE-013,
W146, pertussis toxin, PP2, PD98059, SB203580, SP600125,
and monoclonal anti-β-actin antibody were obtained from
Sigma-Aldrich (St. Louis, MO, USA). VPC23019 was purchased
from Avanti Polar Lipid Inc. (Birmingham, AL, USA). The
cholesterol-loaded MβCD (CLM) was prepared as described
by Purdy and Graham (2004). Mouse VEGF-A164 Affinity
Purified Polyclonal Antibody (AF-493-NA) and recombinant
mouse VEGF-A164 (494-MV) were obtained from R&D Systems
(Minneapolis, MN, USA). [3H]-thymidine was obtained from
DuPont/NEN (Boston, MA, USA). Phospho-ERK, phospho-JNK/
SAPK, phospho-p38, and phospho-Flk-1 antibodies were
obtained from Cell Signaling Technology Inc. (Beverly, MA,
USA). The rabbit anti-S1P1 (EDG1) and anti-S1P3 (EDG3)
antibodies were purchased from Abcam (Cambridge, MA,
US), which were prepared against synthetic peptides
representing amino acids 359–372 (SHPQKDDGDNPETI) of
mouse EDG1 and corresponding to N terminal amino acids
10–30 (QPVRGNETLREHYQYVGKLAG conjugated to KLH) of
Human EDG3, respectively. And rabbit anti-S1P2 (EDG5)
Table 1 Primary antibodies used in present study.
Antibody Manufacturer Dilution concentration for immunoblotting
EDG-1 (S1P1) Abcam 1:1000 (for immunostaining 1:100)
EDG-5 (S1P2) Thermo Scientific 1:1000 (for immunostaining 1:100)
EDG-3 (S1P3) Abcam 1:1000 (for immunostaining 1:100)
Caveolin-1 Santa Cruz Biotechnology Inc. 1:1000 (for immunostaining 1:100)
Cyclin D1 Santa Cruz Biotechnology Inc. 1:1000
CDK4 Santa Cruz Biotechnology Inc. 1:1000
Cyclin E Santa Cruz Biotechnology Inc. 1:1000
CDK2 Santa Cruz Biotechnology Inc. 1:1000
β-Arrestin Cell Signaling Technology Inc. 1:1000 (for immunostaining 1:100)
Phospho-src Cell Signaling Technology Inc. 1:1000
Flk-1 Cell Signaling Technology Inc. 1:1000 (for immunostaining 1:100)
Phospho-Flk-1 Cell Signaling Technology Inc. 1:1000
VEGF Santa Cruz Biotechnology Inc. 1:1000
Phospho-ERK Santa Cruz Biotechnology Inc. 1:1000
Phospho-JNK Santa Cruz Biotechnology Inc. 1:1000
Phospho-p38 Santa Cruz Biotechnology Inc. 1:1000
β-Actin Santa Cruz Biotechnology Inc. 1:1000
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representing amino acids 325–343 (LLPLRSSSSLERGMHMPTS)
of EDG5 was provided by Thermo Scientific (Waltham,
MA, USA). The specificity of S1P receptor antibodies was
confirmed by downregulation of S1P1 and S1P3 proteins
using siRNA transfection in Western blot analysis (Suppl
Fig. S1). Anti-caveolin-1, anti-Flk-1, anti-CDK4, anti-CDK2,
anti-cyclin D1, and anti-cyclin E antibodies were purchased
from Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA).
The goat anti-rabbit IgG was supplied by Jackson Immuno-
Research (West Grove, PA, USA). Liquiscint was obtained
from National Diagnostics (Parsippany, NY, USA). All other
reagents were of the highest purity commercially available
and were used as received. Also, the antibodies, chemicalTable 2 Chemical agonists and antagonists use in present
study.
Chemical Final
concentration
Manufacturer
Sphingosine-1-
phosphate (S1P)
5 μM Sigma-Aldrich
Mouse VEGF-A164
Affinity Purified
Polyclonal Antibody
1 μg/ml R&D Systems
Recombinant mouse
VEGF-A164
20 ng/ml R&D Systems
Methyl-β-cyclodextrin
(MβCD)
1 mM Sigma-Aldrich
VPC23019 1 μM Avanti Polar Lipid Inc.
JTE-013 10 μM Sigma-Aldrich
W146 10 μM Sigma-Aldrich
Pertussis toxin (Ptx) 100 ng/ml Sigma-Aldrich
PP2 1 μM Sigma-Aldrich
VEGFR2 kinase
inhibitor (SU1498)
2 μM Merck KGaA
PD98059 10 μM Sigma-Aldrich
SB203580 1 μM Sigma-Aldrich
SP600125 1 μM Sigma-Aldrichagonists, and antagonist used in the present study are de-
scribed in Tables 1 and 2.
Cell culture and agonist/antagonist treatment
The mouse ES cells (ES-E14TG2a and ES-R1) were cultured
in Dulbecco's Modified Eagle's Media (DMEM) (Gibco-BRL;
Gaithersburg, MD, USA) supplemented with 3.7 g/l so-
dium bicarbonate, 1% penicillin and streptomycin, 1.7 mM
L-glutamine, 0.1 mM β-mercaptoethanol, 5 ng/ml mouse
leukemia inhibitory factor (LIF), and 15% FBS, without a
feeder layer. The cells were grown on 12-well plates or
60-mm culture dishes in an incubator maintained at 37 °C in
humidified atmosphere containing 5% CO2. After two to
three days of culture, cells were washed twice with phos-
phate buffered saline (PBS) and maintained in serum-free
DMEM, which contained all other supplements at the concen-
trations indicated above to synchronize ES cells. After a 24 h
incubation period, the cells were washed twice with PBS
and given fresh serum-free media containing the designated
agents for the time periods indicated. For lipid raft dis-
ruption, MβCD (1 mM) or CLM (1 mM) was treated for 1 h and
then the culture media were changed with MβCD- or CLM-
free fresh media.
Reverse transcription-PCR & real-time PCR
The ES cells (ES-E14TG2a and ES-R1) were maintained in
serum-free DMEM for 24 h. After refreshing the culture
media with serum-free DMEM, the cells were incubated
for 12 h with/without S1P (5 μM) and the total RNA was
extracted from the cells using STAT-60, a monophasic
solution of phenol and guanidine isothiocyanate (Tel-Test,
Inc.; Friendswood, TX, USA). Reverse transcription was
carried out using 1 μg of RNA using a reverse transcription
system kit (RT PreMix; AccuPower, Daejeon Korea) with the
oligo(dT18) primers. Two microliters of the reverse tran-
scription (RT) products was then amplified using a polymer-
ase chain reaction (PCR) kit (PCR PreMix; AccuPower).
Table 3 Primers used for real-time PCR.
Gene Identification Primer sequence, 5′–3′
Mouse
S1P1
Sense
Antisense
GATATCATCGTCCGGCATTAC
ACCCTTCCCAGTGCATTGTTC
Mouse
S1P2
Sense
Antisense
TATCGTGGCTCTGTACGTCC
CGCCACGTATAGATGACAGG
Mouse
S1P3
Sense
Antisense
GACTGCTCTACCATCCTGCCC
GTAGATGACAGGGTTCATGGC
Mouse
S1P4
Sense
Antisense
AAGACCAGCCGTGTGTATGG
TCAGCACGGTGTTGAGTAGC
Mouse
S1P5
Sense
Antisense
ACTCACTTCTGAACCCCATCATCTAC
CTGTGGAGCCGCTGGTGTC
Oct 4 Sense
Antisense
CGTGAGACTTTGCAGCCTGA
GGCGATGTAAGTGATCTGCTG
Sox2 Sense
Antisense
GTGGAAACTTTTGTCCGAGAC
TGGAGTGGGAGGAAGAGGTAAC
Nanog Sense
Antisense
CTATGATCTTTCCTTCTAGACACTG
AGCCCAAAGCTTGCGTAAGTCTCATATT
β-Actin Sense
Antisense
AACCGCGAGAAGATGACCCAGATCATGTTT
AGCAGCCGTGGCCATCTCTTGCTCGAAGTC
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Rotor-Gene 6000 real-time thermal cycling system (Corbett
Research; NSW, Australia) using QuantiTect SYBR Green
PCR Kits (QIAGEN; Valencia, CA, USA). The primers used are
described in Table 3. The reaction mixture (20 μl) contained
200 ng of total RNA, 0.5 μM of each primer, and appropriate
amounts of enzymes and fluorescent dyes as recommended
by the supplier. The PCR and real-time PCR were performed
as follows: 30 min at 50 °C for reverse transcription; 15 min
at 95 °C for DNA polymerase activation; 15 s at 95 °C for
denaturing; and 45 cycles of 15 s at 94 °C, 30 s at 55 °C, and
30 s at 72 °C. Data collection was carried out during the
extension step (30 s at 72 °C) and analysis was performed
using the software provided by the manufacturer. Following
real-time PCR, melting curve analysis was performed to
verify the specificity and identity of the PCR products.
Western blot analysis
Cells were harvested, washed twice with PBS, and lysed in
lysis buffer (20 mM Tris [pH 7.5], 1 mM EDTA, 1 mM EGTA,
1% Triton X-100, 1 mg/ml aprotinin, 1 mM phenylmethyl-
sulfonylfluoride (PMSF), and 0.5 mM sodium orthovanadate)
for 30 min on ice. The lysates were cleared by centrifugation
(30 min at 15,000 rpm, 4 °C), and the protein concentration
was determined using the Bradford method (Bradford,
1976). Equal amounts of protein (20 μg) were resolved by
10% SDS-PAGE and transferred to polyvinylidene difluoride
(PVDF) membranes. The membranes were washed with
TBST (10 mM Tris–HCl [pH 7.6], 150 mM NaCl, and 0.01%
Tween-20), blocked with TBST containing 5% skim milk for
1 h, and incubated with the appropriate primary antibodies
at the dilutions recommended by the suppliers. The mem-
branes were then washed and the primary antibodies were
detected with goat anti-rabbit IgG or goat anti-mouse
IgG conjugated to horseradish peroxidase. Immunoreactive
proteins were visualized by enhanced chemiluminescence
(Amersham Pharmacia Biotech; Buckinghamshire, UK). Theresults were measured by optical density using TINA 2.0 and
presented as means ± SEM.Immunocytochemistry
Cells were fixed with 4% paraformaldehyde for 20 min,
permeabilized with 0.25% Triton X-100/PBS for 5 min, and
blocked in 10% fetal bovine serum in 0.1% Triton X-100/PBS
for 20 min. The cells were labeled with anti-caveolin-1,
anti-S1P1, anti-S1P2, anti-S1P3, anti-Flk-1, or anti-β-arrestin
antibodies at a ratio of 1:100, followed by fluorescein
isothiocyanate (FITC)-conjugated anti-mouse IgM at 1:100,
or Alexa Fluor® 555 goat anti-rabbit IgG at 1:400 for 1
each at room temperature. Images were obtained using
a FluoView™ 300 confocal microscope (Olympus; Tokyo,
Japan).Proximity ligation assay
Cells were fixed in 4% paraformaldehyde/PBS for 20 min,
permeabilized with 0.25% Triton X-100/PBS for 5 min, and
blocked in 10% fetal bovine serum in 0.1% Triton X-100/PBS
for 20 min. Primary antibodies (anti-S1P1, anti-S1P2, anti-
S1P3, or anti-Flk-1) diluted in antibody dilution solution
supplied by the manufacturer were added for 2 h. Duolink
(Olink Biosciences; Uppsala, Sweden) in situ proximity ligation
assay (PLA) was performed according to the manufacturer's
protocol. PLA probes were diluted in 0.1% Triton X-100/PBS/
1% fetal calf serum and incubated in a pre-heated humidity
chamber for 1 h at 37 °C, followed by hybridization, ligation,
amplification, counterstaining with propidium iodide (PI) in
PBS containing 1% (v/v) BSA, and detection. The distance
between the two primary antibodies needs to be less than
40 nm to generate a signal in this assay, making the method-
ology highly specific for physically interacting protein–protein
complexes. Samples were mounted on slides and visualized
with a FluoView™ 300 confocal microscope (Olympus; Tokyo,
Japan) with 400× objective for imaging.Co-immunoprecipitation
The complex formation between S1P1, S1P3, and β-arrestin
or Flk-1 was analyzed by immunoprecipitation and Western
blotting. Cells were lysed with the co-immunoprecipitation
buffer (1% Triton X-100 in 50 mM Tris–HCl [pH 7.4] contain-
ing 150 mM NaCl, 5 mM EDTA, 2 mM Na3VO4, 2.5 mM
Na4PO7, 100 mM NaF, 200 nM microcystin lysine–arginine,
and protease inhibitors). Cell lysates (300 μg) were mixed
with 10 μg of anti-β-arrestin or anti-Flk-1 antibody. The
samples were incubated for 4 h, and Protein A/G PLUS-
agarose immunoprecipitation reagent (Pierce; Rockford, IL,
USA) was then added and the samples were incubated for
an additional 12 h. The beads were washed four times with
the co-immunoprecipitation buffer, and the bound proteins
were released from the beads by boiling in sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) sam-
ple buffer for 5 min. Samples were analyzed by Western
blotting with anti-S1P1 and anti-S1P3 antibodies.
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Cells were dissociated in trypsin/EDTA, pelleted by centri-
fugation, and resuspended at approximately 106 cells/ml in
PBS containing 0.1% BSA. The cells were then fixed with 70%
ice-cold ethanol for 30 min at 4 °C, followed by incubation
in a freshly prepared nuclei staining buffer consisting of
250 μg/ml propidium iodide (PI) and 100 μg/ml RNase for
30 min at 37 °C. Cell cycle histograms were generated after
analyzing the PI-stained cells by the Cell Lab Quanta™ SC
flow cytometer (Beckman Coulter Inc.; Brea, CA, USA). The
samples were analyzed using CXP software (Beckman Coulter
Inc.) and the proliferation indices [(S + G2/M) / (G0/G1 +
S + G2/M)] were calculated.Cell number counting
To determine the total cell number, the cells were washed
twice with PBS and the cells in the culture dishes were
trypsinized. The cell suspension was mixed with a 0.4% (w/v)
trypan blue solution, and the number of live cells was
determined using a hemocytometer. Cells failing to exclude
the dye were considered nonviable.[3H]thymidine incorporation
The [3H]thymidine incorporation experiments were per-
formed as previously described by Brett et al. (1993).
Briefly, mouse ES cells were synchronized in the G0/G1
phase by culture in serum-free media for 24 h before
stimulation with S1P. After the incubation period, 1 μCi
of [methyl-3H]thymidine (specific activity: 74 GBq/mmol,
2.0 Ci/mmol; Amersham Biosciences; Buckinghamshire, UK)
was added to the cultures for 1 h at 37 °C. Cellular [3H]
thymidine uptake was quantified by liquid scintillation
counting in the harvested cellular material. All values were
converted from absolute counts to percentages of control
and reported as means ± standard error of mean (SEM) of
triplicate experiments.Table 4 siRNA sequence for transfection.
Target gene Sequences 5′–3′ Manufacturer
β-Arrestin UCGAGUGAUUAUUACGUCA
UGACGUAAUAAUCACUCGA
Bioneer
VEGF GCAGAAUCAUCACGAAGUG-
CAACAAAUGUGAAUGCAGA-
GGAGUACCCUGAUGAGAUC-
GAUCAAACUCACCAAGGCC
Dharmacon
Non-targeting CCUACGCCACCAAUUUCGU
ACGAAAUUGGUGGCGUAGG
UGGUUUACAUGUCGACUAA
UUAGUCGACAUGUAAACCA
DharmaconSucrose density gradient fractionation
Detergent-free purification of caveolin-rich membrane frac-
tions was performed to prepare caveolin-enriched mem-
brane fractions as described previously (Song et al., 1996).
Cells were washed twice with ice-cold PBS and scraped into
2 ml of 500 mM sodium carbonate (pH 11.0), transferred to a
plastic tube, and homogenized using a sonicator (three 20-s
bursts; Branson Sonicator 250, Branson Ultrasonic Corp.,
Danbury, CT, USA). The homogenate was then adjusted to
45% sucrose by the addition of 2 ml of 90% sucrose prepared
in MES-buffered solution [MBS: 25 mM MES (pH 6.5), 0.15 M
NaCl] and placed at the bottom of an ultracentrifuge tube.
A 5–35% discontinuous sucrose gradient was formed above
(4 ml of 5% sucrose, 4 ml of 35% sucrose, both in MBS
containing 250 mM sodium carbonate) and centrifuged at
40,000 rpm for 20 h in an SW41 rotor (Beckman Instruments).
Twelve 1-ml fractions were collected and analyzed by SDS-
polyacrylamide gel electrophoresis (PAGE).Preparation of cytosolic and total membrane fractions
The cytosolic and total membrane fractions were prepared
using a modification of the method reported by Mackman
et al. (1991). The cells were washed with ice-cold PBS
and harvested by centrifugation and resuspended in buffer
A [137 mM NaCl, 8.1 mM Na2HPO4, 2.7 mM KCl, 1.5 mM
KH2PO4, 2.5 mM EDTA, 1 mM dithiothreitol, 0.1 mM PMSF,
10 g/ml leupeptin (pH 7.5)]. The resuspended cells were
then mechanically lysed on ice by trituration with a 21.1-
gauge needle. The lysates were first centrifuged at 1,000 ×g
for 10 min at 4 °C. The cytosolic and total particulate
fractions were prepared by centrifuging the supernatants
at 100,000 ×g for 1 h at 4 °C. The supernatants (cytosolic
fraction) were then precipitated with 5 vol. of acetone,
incubated for 5 min on ice and centrifuged at 20,000 ×g for
20 min at 4 °C. The pellets were resuspended in buffer A
containing 1% (v/v) Triton X-100. The particulate fractions
containing the membrane fraction were then washed and
resuspended in buffer A containing 1% (v/v) Triton X-100.
The protein concentration in each fraction was determined
using the Bradford procedure (Bradford, 1976).Small interfering RNA (siRNA) transfection
ES cells were grown until 75% confluence. The cells were
transfected for 24 h with β-arrestin-specific siRNA (25 nM;
Bioneer, Daejeon, Republic of Korea), VEGF siRNA (25 nM;
Dharmacon, Lafayette, CO, USA), or non-targeting siRNA
(25 nM) as a negative control (Dharmacon) using DharmaFECT
transfection reagent (Dharmacon). The siRNA used is de-
scribed in Table 4. After 6 h of incubation, the culture media
were replaced with transfection mixture-free and serum-free
media and the cells were maintained until 24 h. The efficacy
of β-arrestin and VEGF specific siRNA was confirmed by
Western blot analysis (Suppl Fig. S2).Statistical analysis
Results are expressed as mean value ± standard error of
mean (SEM). All experiments were analyzed by ANOVA, and
some experiments which needed to compare with ≥3 groups
were examined by comparing the treatment means to the
Figure 1 Localization of S1P1–3 in lipid rafts. The mouse ES cells (E14TG2a and R1) were treated with S1P (5 μM) for 12 h and the
total RNA was extracted as described in the ‘Materials and methods’ section. The transcriptional levels of the S1P receptors 1–5
(S1P1–5) were detected with reverse-transcription (RT)-PCR and real-time RT-PCR. And the water placed in cDNA was used as a
negative control (N) (A, B). Data are presented as mean ± standard error of mean (SEM) of three different experiments, each from
triplicate dishes. *P b 0.05 versus control. The mouse ES cells were double labeled with S1P1–3 and caveolin-1 (cav-1). To confirm the
antibodies specificity, S1P1–3 or caveolin-1 antibodies isotype-matched normal rabbit IgG or normal mouse IgG were used as an
isotype control. (C). The example shown is representative of four experiments. The scale bars represent 20 μm. The total cell lysates
were subjected to discontinuous sucrose density gradient fractionation, and then S1P1–3 and cav-1 were detected (D). Each fraction
was assessed by Western blot. After the cell culture media were changed with serum-free media, mouse ES cells were treated with
S1P (5 μM) for 12, 24, and 48 h. The total RNA was extracted as described in the ‘Materials and methods’ section. The transcriptional
levels of the mouse ES cell undifferentiation markers (Oct4, Sox2, or Nanog) were detected with RT-PCR and real-time RT-PCR (E).
The water placed in cDNA was used as a negative control (N) in RT-PCR. Data are presented as mean ± standard error of mean (SEM) of
three different experiments, each from triplicate dishes.
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considered statistically significant.Results
S1P receptors were expressed in mouse ES cells and
localized in lipid rafts
In order to determine the presence of S1P receptors in
mouse ES cells, we incubated the mouse ES cells (E14TG2a
and R1) with S1P for 12 h and examined the S1P1–5 mRNA
expression level. All isotypes of S1P receptor mRNA were
expressed in mouse ES cells and S1P treatment significantly
increased S1P1, S1P2, and S1P3 expression levels (Figs. 1A
and B). In order to examine the location of S1P receptors
on the plasma membrane, the cells were immunostained
with S1P1, S1P2, S1P3, or caveolin-1 (cav-1) antibodies. The
specificity of anti-S1P1, -S1P2, and -S1P3 was confirmed by
downregulation of target proteins using siRNA transfection
(Suppl Fig. 1). The staining revealed that S1P1, S1P2, and
S1P3 are co-localized with cav-1 used as a lipid raft marker
(Fig. 1C). In addition, the plasma membrane lipid raft
fraction was found to reside mainly in the light buoyant
membranes (fraction #s 4–6). Western blot analysis showed
that S1P1 and S1P3 are mainly located in lipid raft fractions,
and S1P1 was also detected in fraction # 12 which could
be due to pellet formation of undisrupted membrane in
ultracentrifuge tube bottom. However, S1P2 was presented
in both lipid raft (fraction #s 4–6) and non-lipid raft fractions
(fraction #s 8–12) (Fig. 1D). Furthermore, in an experiment
to confirm the effect of S1P on mouse ES cell pluripotency,
S1P treatment and serum deprivation up to 48 h did not
significantly alter the mRNA expression level of Oct4, Sox2,
and Nanog, suggesting that the S1P treatment did not
change the undifferentiated status of mouse ES cells under
the experimental conditions used in this study (Fig. 1E).S1P induced G1–S phase transition in mouse ES cells
via S1P1/3
To examine the effect of S1P on mouse ES cell proliferation,
the cells were treated with various concentrations of S1P
(0–10 μM) for 24 h or incubated with S1P (5 μM) for different
periods of time (0–48 h) and then the cell cycle regulatory
protein (cyclin D1/CDK4 and cyclin E/CDK2) expression level
and DNA synthesis were observed. The cell cycle regulatory
protein expression were increased in a dose (from 0.1 to
10 μM)- and time (from 12 to 48 h)-dependent manner. In
addition, S1P increased cell cycle regulatory protein ex-
pression of mouse ES-R1 cells in a dose-dependent manner
(Figs. 2A and B). Consistent with these results, we observed
a significant increase in [3H]thymidine incorporation after
incubating the cells with more than 0.1 μM S1P for more
than 12 h (Figs. 2C and D). These results were confirmed
by the observation of an increased proliferation index and
cell number in S1P-stimulated cells (Figs. 2E and F). To
investigate whether the effect of S1P on ES cell proliferation
is dependent on specific S1P receptor isotypes located in
the lipid raft, the cells were pretreated with 1 mM methyl-
β-cyclodextrin (MβCD; lipid raft disruptor), cholesterol-loadedMβCD (1 mM; CLM), VPC23019 (1 μM; S1P1/3 inhibitor), JTE-013
(10 μM; S1P2 inhibitor), or W146 (10 μM; S1P1 inhibitor) for
1 h prior to treatment with S1P. The S1P-induced increase
in cell cycle regulatory protein expression was blocked by
lipid raft disruption and inhibition of S1P1/3, but not by S1P2
inhibition (Figs. 2G and H), which was supported by the
results of [3H]thymidine incorporation and proliferation
index (Figs. 2I and J).
S1P enhanced S1P1/3-dependent β-arrestin
translocation and c-Src phosphorylation
The translocation of β-arrestin from cytosol to membrane
in response to S1P was examined. As shown in Fig. 3A,
S1P-induced translocation of β-arrestin was inhibited by
pretreatment with VPC23019 or W146, but not by pretreat-
ment with JTE-013. In addition, pretreatment with pertussis
toxin (Ptx, 100 ng/ml), ADP-ribosylation of Gα subunit,
blocked the S1P-induced β-arrestin translocation (Fig. 3B).
These results suggest that the activation of S1P1 and S1P3,
coupled with Gαi protein, elicited β-arrestin translocation.
Next, the cells were pretreated with MβCD or Ptx for 1 h
prior to incubation with S1P or VEGF-A164, and analyzed
by immunoprecipitation and Western blotting. As deter-
mined by immunoprecipitation experiments, S1P treatment
stimulated the signaling complex formation of S1P1 or S1P3
with β-arrestin, but VEGF-A164 treatment had no effects on
binding of S1P receptors to β-arrestin (Fig. 3C). In addition,
pretreatment with MβCD or Ptx blocked S1P-induced binding
of β-arrestin to S1P1 or S1P3. S1P treatment stimulates
translocation of β-arrestin to the membrane, which was
inhibited by VPC23019, W146, or Ptx pretreatment (Fig. 3D).
Furthermore, S1P treatment stimulates the phosphorylation
of c-Src in a time-dependent manner (Fig. 3E), which was
attenuated by VPC23019, W146, or Ptx pretreatment and
β-arrestin siRNA transfection (Figs. 3F–H).
S1P elicited signaling complex formation of S1P1/3
with Flk-1 and transactivated Flk-1
The expression of Flk-1 in undifferentiated ES cells was
confirmed by detection of Flk-1 mRNA and protein expres-
sion level. In addition, most of ES cells were expressed in
both Flk-1 and Oct4 proteins (Suppl Fig. S3). To determine
whether S1P elicits Flk-1 translocation to the lipid rafts in
the plasma membrane, the cells were double labeled with
Flk-1 and cav-1, and this revealed that the Flk-1 was located
in the lipid rafts (Fig. 4A). Consistently, in an experiment
using sucrose density gradient fractionation, Flk-1 was
located in the lipid raft fraction and S1P treatment in-
creased the Flk-1 protein level in the lipid raft fraction,
which was blocked by lipid raft disruption using MβCD
(Figs. 4B and C). To examine the binding between S1P
receptor and Flk-1, the cells were treated with S1P or
VEGF-A164. S1P treatment increased the protein levels of
S1P1 or S1P3 precipitated with Flk-1, but VEGF-A164 treat-
ment did not affect the protein levels of S1P1 or S1P3
precipitated with Flk-1. In addition, S1P-induced signaling
complex formation of Flk-1 with S1P1 or S1P3 was inhibited
by Ptx (100 ng/ml), PP2 (1 μM) pretreatment or β-arrestin
siRNA transfection (Fig. 4D). To confirm the interaction
Figure 2 S1P induced G1–S phase transition in mouse ES cells. The ES cells (E14TG2a and R1) were treated with various
concentrations of S1P (0–10 μM) for 24 h, and then the cell cycle regulatory protein (CDK4/cyclin D1, CDK2/cyclin E) expressions
were detected in the total cell lysates (A). The ES cells were incubated for various periods of time (0–48 h) with 5 μM of S1P and the
cell cycle regulatory protein expressions were detected (B). The right panel depicted by bars denotes mean ± SEM of three
experiments for each condition determined by densitometry relative to β-actin. *P b 0.05 versus control. The cells were treated with
different concentrations of S1P (0–10 μM) for 24 h or incubation for various time points (0–48 h) with 5 μM of S1P and were pulsed
with 1 μCi of [3H]thymidine for 1 h (C, D). Data are presented as mean ± SEM of three different experiments, each from triplicate
dishes. *P b 0.05 versus control. The mouse ES cells were treated with various concentrations of S1P for 24 h. And cells were then
washed with PBS, fixed, stained, and analyzed by flow cytometry (E). Gates were manually configured to determine the percentage
of cells in S phase based on DNA content. The data was calculated using the proliferation index [(S + G2/M) / (G0/G1 + S + G2/M)].
The number of cells was counted using a hemocytometer (F). The data was reported as the mean ± SEM of four different experiments,
each conducted in triplicate. *P b 0.05 versus control. The cells were pretreated with MβCD (1 mM) or CLM (1 mM) for 1 h and then
the culture media were changed with Mβ-CD free media prior to treatment with S1P for 24 h. And the cell cycle regulatory protein
(CDK4, CDK2, cyclin D1, and cyclin E) expression was detected (G). The ES cells were pretreated with VPC23019 (1 μM; S1P1/3
inhibitor), JTE-013 (10 μM; S1P2 inhibitor), and W146 (10 μM; S1P3 inhibitor) for 1 h prior to treatment with S1P for 24 h and detected
cell cycle regulatory protein expression (H). The right part depicted by bars denotes mean ± SEM of three experiments for each
condition determined by densitometry relative to β-actin. *P b 0.05 versus control, **P b 0.05 versus S1P alone. After treatment of
the cells as describe in (G) and (H), the cells were pulsed with 1 μCi of [3H]thymidine for 1 h (I), or the cells analyzed by flow
cytometry (J). Data are presented as mean ± SEM of three different experiments, each from triplicate dishes. *P b 0.05 versus
control, **P b 0.05 versus S1P alone.
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Figure 3 S1P enhanced β-arrestin translocation and c-Src phosphorylation. The cells were pretreated with VPC23019, JTE-013,
W146, or pertussis toxin (Ptx, 100 ng/ml; Gi protein inhibitor) for 1 h prior to treatment with S1P (5 μM) for 30 min and the cell
lysates were separated into cytosolic or plasma membrane fractions and detected the β-arrestin by Western blot analysis, as
described in the ‘Materials and methods’ section (A, B). The lower part depicted by bars denotes mean ± SEM of three experiments
for each condition determined by densitometry relative to β-actin. *P b 0.05 versus cytosol control, #P b 0.05 versus membrane
control. Mouse ES cells were treated with either S1P (5 μM) or VEGF-A164 (20 ng/ml) for 30 min or pretreated with MβCD or Ptx for 1 h
prior to incubation with S1P for 30 min. The total cell lysates and immunoprecipitation of anti-β-arrestin were analyzed by Western
blotting with antibodies that recognize S1P1 or S1P3 (C). The lower part depicted by bars denotes mean ± SEM of three experiments
for each condition determined by densitometry. *P b 0.05 versus control, **P b 0.05 versus S1P alone. The cells were pretreated with
VPC23019, JTE-013, W146, or Ptx for 1 h before treatment with S1P for 30 min and double labeled with anti-β-arrestin and PI and
observed with a confocal microscope. Normal rabbit IgG was used as an isotype control (D). Insets show magnified versions of sections
in the white boxes. The example shown is representative of four experiments. The scale bars represent 50 μm. The profiles in the
panel below show the fluorescence intensity of β-arrestin from line (white solid line) scans in the merged images, which were
analyzed by FluoView™ 300 software (Olympus; Tokyo, Japan). Cells were treated with 5 μM of S1P for different time periods
(0–120 min) and phosphorylation of c-Src was detected (E). After incubation with VPC23019, JTE-013, W146, or Ptx for 1 h or
β-arrestin siRNA for 24 h, the cells were treated with S1P for 30 min, the total cell lysates were subjected to SDS-PAGE for detection
of c-Src phosphorylation (F–H). The lower part depicted by bars denotes mean ± SEM of three experiments for each condition
determined by densitometry relative to β-actin. *P b 0.05 versus control, **P b 0.05 versus S1P alone.
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78 J.M. Ryu et al.between the S1P receptors and Flk-1, we performed in situ
proximity ligation assay (PLA) with or without S1P treatment.
The confocal microscopy collected at 0.38 μm intervals and
merged together, showed that S1P induced an increase in the
number of S1P1 or S1P3 interactions with Flk-1 (Fig. 4E, green
dots represent the detected interaction). Thus, next, we
measured the effect of S1P on Flk-1 phosphorylation and
the involved downstream molecules. S1P treatment increasedFlk-1 phosphorylation in a dose (0.1–10 μM) and time (15–
120 min)-dependent manner (Figs. 5A and B). In addition, S1P
or VEGF-A164 treatment increased Flk-1 phosphorylation and
pretreatment with VPC23019, W146, or PP2 and transfection of
β-arrestin siRNA blocked the S1P-induced increase in Flk-1
phosphorylation (Figs. 5C–E), thereby demonstrating that the
S1P-induced Flk-1 phosphorylation is mediated by S1P1/3-
dependent β-arrestin and c-Src activation.
Figure 5 S1P-induced Flk-1 phosphorylation is mediated by β-arrestin and c-Src. The mouse ES cells were treated with various
concentrations of S1P (0–10 μM) for 30 min or incubated for various time points (0–120 min) with S1P. And the total cell lysates were
subjected to Western blotting with anti-phospho-Flk-1, anti-Flk-1, or anti-β-actin (A, B). The cells were pretreated with VPC23019,
JTE-013, W146, and PP2 for 1 h or transfected with β-arrestin-specific siRNA for 24 h prior to incubation with S1P for 1 h and the
phosphorylation of Flk-1 was analyzed (C–E). The lower part depicted by bars denotes mean ± SEM of three experiments for each
condition determined by densitometry relative to β-actin. *P b 0.05 versus control, **P b 0.05 versus S1P alone.
Figure 4 S1P induced signaling complex formation between S1P1/3 and Flk-1. The mouse ES cells were double labeled with Flk-1
and cav-1 (A). The example shown is representative of four experiments. The cells were pretreated with MβCD (1 mM) for 1 h and the
culture media were changed with MβCD-free media prior to treatment of S1P for 1 h. The cell lysates were separated with sucrose
density gradient fractionation and the Flk-1 and cav-1 were examined (B). The same volumes of lipid raft fraction (#s 4–6) or non-lipid
raft fraction (#s 9–11) were subjected to SDS-PAGE and detected with Flk-1 antibody (C). Mouse ES cells were treated with either S1P
(5 μM) or VEGF-A164 (20 ng/ml) for 1 h. The total cell lysates and immunoprecipitation of anti-Flk-1 were analyzed by Western
blotting with antibodies that recognize S1P1 or S1P3. In addition, the cells were pretreated with Ptx (100 ng/ml), or PP2 (1 μM) for 1 h
or transfected with β-arrestin-specific siRNA for 24 h. The cell lysates were immunoprecipitated with anti-Flk-1 antibody and
analyzed with S1P1 or S1P3 antibodies (D). Normal mouse IgG was used as an isotype control. The right part depicted by bars denotes
mean ± SEM of three experiments for each condition determined by densitometry. *P b 0.05 versus control, **P b 0.05 versus
S1P alone. After incubation with 5 μM S1P, the cells were incubated with S1P1–3 or Flk-1 antibodies and analyzed with
immunofluorescence confocal microscopy in combination with in situ PLA, which detects protein–protein complex (E). Insets show
magnified versions of sections in the white boxes. Each detected green dot represented protein complexes and nuclei were
counterstained by PI (red). The scale bars represent 100 μm.
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Figure 6 S1P-induced VEGF synthesis/secretion is involved in ES cell proliferation. The cells were treated with different con-
centrations of S1P (0–10 μM) for 24 h or incubated for various time points (0–48 h) with 5 μM of S1P. And VEGF protein expression was
detected with Western blotting (A, B). Mouse ES cells were pretreated with VPC23019, JTE-013, W146, Ptx, MβCD or CLM for 1 h prior
to treatment with S1P (5 μM) for 24 h and VEGF was detected in the total cell lysates or ES cell culture medium (C–E). The lower part
depicted by bars denotes mean ± SEM of three experiments for each condition determined by densitometry relative to β-actin.
*P b 0.05 versus control, **P b 0.05 versus S1P alone. The cells were treated with various concentrations of VEGF-A164 (0–20 ng/ml)
for 24 h and CDK4, CDK2, cyclin D1, and cyclin E expressions were detected (F). The right part panel denotes mean ± SEM of three
experiments for each condition determined by densitometry relative to β-actin. *P b 0.05 versus control.
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proliferation
S1P treatment increased the VEGF expression in a dose-
and time-dependent manner, which was blocked by pre-
treatment with VPC23019 and W146, but not by pretreat-
ment with JTE-013 (Figs. 6A–C). In addition, Ptx and MβCD
pretreatment blocked the S1P-induced increase in VEGF
production and secretion (Figs. 6D and E). Therefore, we
examined the effect of extracellular VEGF on mouse ES
cell proliferation and Flk-1 activation. VEGF-A164 treat-
ment increased the expression of cyclins/CDKs in a dose-
dependent manner, and the maximum increase was ob-
served at 20 ng/ml of VEGF-A164 (Fig. 6F). In addition, S1P
and/or VEGF-A164 treatment for 30 min stimulates the Flk-1
phosphorylation (Fig. 7A). However, the interval between
S1P-induced Flk-1 phosphorylation and VEGF production
suggests the possibility that the S1P could directly
transactivate the Flk-1, not mediated by VEGF. Thus, to
examine whether the S1P-induced Flk-1 phosphorylation
occurred in direct transactivation manner, irrespective
of extracellular VEGF, the cells were pretreated with
VEGF-A164 neutralizing antibodies (VEGF Ab), or VEGF
siRNA prior to incubation with S1P for 1 h. S1P-inducedFlk-1 phosphorylation was not inhibited by pretreatment
with VEGF-A164 Ab and VEGF siRNA (Figs. 7B and C),
suggesting that the S1P can elicit Flk-1 transactivation
without extracellular VEGF. Interestingly, pretreatment with
VEGFR2 kinase inhibitor (SU1498) blocked the S1P-induced cell
cycle regulatory protein expression, but pretreatment with
VEGF-A164 Ab, and VEGF siRNA partially blocked the S1P-
induced cell cycle regulatory protein expression (Figs. 7D–F).
These results were supported by the results of [3H]thymidine
incorporation and proliferation index (Figs. 7G and H),
suggesting that both VEGF-dependent Flk-1 activation and
VEGF-independent Flk-1 activation contributed to S1P-induced
ES cell proliferation.S1P-dependent Flk-1 transactivation
stimulated MAPKs
To investigate the downstream targets of S1P-induced Flk-1
activation, we treated the cells with S1P for various periods
of time (0–90 min) or pretreated the cells with VPC23019,
JTE-013, or W146 for 1 h prior to incubation with S1P for 1 h.
S1P increased the phosphorylation levels of ERK and JNK,
but not of p38 (Fig. 8A). In addition, VEGF-A164 increased
Figure 7 S1P stimulated ES cell proliferation through both direct transactivation of Flk-1 and VEGF production. The mouse ES cells
were treated with S1P (5 μM) and/or VEGF-A164 (20 ng/ml) for 1 h, and detected the Flk-1 phosphorylation (A). Cells were pretreated
with VEGF-A164 neutralizing antibody (20 ng/ml) for 1 h or transfected with VEGF specific siRNA for 24 h prior to treatment with S1P
for 1 h and Flk-1 phosphorylation was detected by Western blotting as described in the ‘Materials and methods’ section (B, C). The
lower part depicted by bars denotes mean ± SEM of three experiments for each condition determined by densitometry relative to
β-actin. *P b 0.05 versus control. Mouse ES cells were pretreated with VEGFR2 kinase inhibitor (2 μM; SU1498), VEGF-A164 Ab, or VEGF
siRNA for 1 h and incubated with S1P for 24 h. The cell cycle regulatory protein (CDK4, CDK2, cyclin D1, and cyclin E) expressions
were detected (D–F). The right part depicted by bars denotes mean ± SEM of three experiments for each condition determined by
densitometry relative to β-actin. *P b 0.05 versus control, **P b 0.05 versus S1P alone. The cells were pretreated with SU1498,
VEGF-A164 Ab, or VEGF siRNA prior to incubation with S1P for 24 h and were pulsed with 1 μCi of [
3H]thymidine for 1 h (G). Data are
presented as mean ± standard error of mean (SEM) of three different experiments, each from triplicate dishes. *P b 0.05 versus
control, **P b 0.05 versus S1P alone. Cells were then washed with PBS, fixed, stained, and analyzed by flow cytometry (H). Gates
were manually configured to determine the percentage of cells in S phase based on DNA content. The data was calculated using the
proliferation index [(S + G2/M) / (G0/G1 + S + G2/M)] and reported as the mean ± SEM of four different experiments, each
conducted in triplicate. *P b 0.05 versus control, **P b 0.05 versus S1P alone.
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ment of S1P and VEGF-A164 synergistically increased ERK and
JNK phosphorylation level (Fig. 8B). Pretreatment with
VPC23019 and W146 inhibited the S1P-induced phosphoryla-
tion of ERK and JNK (Fig. 8C). Furthermore, SU1498 blocked
the S1P-induced ERK and JNK phosphorylation, but not by
VEGF-A164 Ab or VEGF siRNA, suggesting that the S1P-
induced ERK and JNK activation occurred by both a VEGF-
dependent and a VEGF-independent manner (Figs. 8D–F).
In addition, the S1P-induced increase in cell cycle regulatory
protein expression and [3H]thymidine incorporation was
blocked by PD98059 and SP600125 (Figs. 8G and H). In
accordance with these results, pretreatment with ERK andJNK inhibitor blocked the S1P-induced increase in prolifer-
ation index (Fig. 8I). Taken together, these results suggest
that the S1P-induced Flk-1 transactivation and activation
of its downstream signaling molecules play an important role
in S1P-induced mouse ES cell proliferation.Discussion
In the present study, we demonstrated that S1P transactivated
Flk-1 through S1P1/3-dependent β-arrestin and c-Src activa-
tion, which sequentially stimulated proliferation of mouse ES
cells. Owing to the variations in S1P functions depending on
Figure 8 ERK and JNK acted as downstream signaling molecules of S1P-induced Flk-1 transactivation. Mouse ES cells were treated
with 5 μM of S1P for different time periods (0–90 min) and phosphorylation of ERK, JNK, or p38 was detected (A). Cells were treated
with S1P (5 μM) and/or VEGF-A164 (20 ng/ml) for 1 h, and detected the ERK and JNK phosphorylation (B). After treatment with
VPC23019, JTE-013, W146, SU1498, or VEGF-A164 Ab for 1 h and transfection with VEGF siRNA for 24 h, the cells were incubated with
S1P for 1 h and the total cell lysates were analyzed by Western blotting with antibodies that recognized phospho-ERK or phospho-JNK
(C–F). The cells were pretreated with PD98059 (10 μM; ERK inhibitor), SB203580 (1 μM; p38 inhibitor), or SP600125 (1 μM; JNK
inhibitor) for 1 h before treatment with S1P for 24 h and the cell cycle regulatory protein (CDK4, CDK2, cyclin D1, or cyclin E)
expressions were detected by Western blotting (G). The right part depicted by bars denotes mean ± SEM of three experiments for
each condition determined by densitometry relative to β-actin. *P b 0.05 versus control, **P b 0.05 versus S1P alone. The cells were
pulsed with 1 μCi of [3H]thymidine for 1 h and [3H]thymidine incorporation was detected as described in the ‘Materials and methods’
section (H). Data are presented as mean ± SEM of three different experiments, each from triplicate dishes. *P b 0.05 versus control,
**P b 0.05 versus S1P alone. Cells were then washed with PBS, fixed, stained, and DNA contents were analyzed by flow cytometry (I).
Gates were manually configured to determine the percentage of cells in S phase based on DNA content. The data was calculated using
the proliferation index [(S + G2/M) / (G0/G1 + S + G2/M)] and reported as the mean ± SEM of four different experiments, each
conducted in triplicate. *P b 0.05 versus control, **P b 0.05 versus S1P alone.
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in mouse ES cells. In accordance with our results, previous
reports demonstrated that mouse ES cells expressed all fiveS1P receptors, but human ES cells expressed only three
S1P receptors (S1P1, S1P2, S1P3) (Inniss and Moore, 2006;
Kleger et al., 2007; Pebay et al., 2005). S1P is physiologically
Figure 9 The proposed model for the signaling pathways
involved in S1P-induced Flk-1 transactivation and proliferation
of mouse ES cells. Sphingosine-1-phosphate (S1P) binding to
S1P1/3 which is located in lipid rafts of the plasma membrane
stimulated β-arrestin translocation from the cytosol to the
membrane and activated c-Src. Subsequently, activated β-arrestin
and c-Src stimulated signaling complex formation between S1P1/3
and Flk-1, and elicited phosphorylation of Flk-1. In addition to
S1P-induced Flk-1 transactivation, S1P also stimulated VEGF
synthesis and secretion which may be involved in Flk-1 phosphor-
ylation. Activated Flk-1 led to the activation of the downstream
molecules including ERK and JNK which subsequently elicited the
cell cycle regulatory protein expression and exerted proliferative
effects on mouse ES cells.
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and 0.2–0.5 μM in serumwhich largely exceed the Kd values of
S1P receptors (Yatomi et al., 1997). In addition, consistent
with previous reports (Che et al., 2012; Kim et al., 2011;
Mascall et al., 2012; Taniguchi et al., 2012), S1P increased
cellular proliferation from 0.1 μM onwards and maximum
increment in cellular proliferation was observed at 1–10 μM
in vitro. Therefore, in this study, we chose to use 5 μM of
S1P. S1P receptors are closely associated with cholesterol-rich
lipid rafts of the plasma membrane, and this association with
lipid rafts is important for the regulation of S1P functions
(Singleton et al., 2006; Zhao et al., 2009). Furthermore, it has
been known that the lipid raft acts as a signaling platform,
which mediates various stem cell responses such as migration
and proliferation (Lee et al., 2010; Sasaki et al., 2011;
Shirvaikar et al., 2010). The effect of S1P on cell cycle
regulation was expected based on previous reports, which
demonstrated that the activation of S1P receptors located in
lipid rafts significantly increased the cell survival by reducing
apoptosis and increasing proliferation of human ES cells and
endothelial cells (Inniss and Moore, 2006; Wong et al., 2007;
Zhao et al., 2009). In the present study, S1P1–3 were located
in both lipid raft and non-lipid raft fractions. The distribution
of S1P receptors was different with isotypes; S1P1 and S1P3
were mainly presented in lipid raft but most of S1P2 was
located in a non-lipid raft fraction which suggests the
possibilities that the role of S1P receptors could be affected
by their membrane location. The disruption of lipid raft
using MβCD significantly attenuated S1P-induced ES cell
proliferation, thereby suggesting that the lipid raft is
involved in the regulation of S1P receptor functions.In various types of cells including stem cells, vascular
endothelial growth factor (VEGF) induces proliferation
primarily through the autophosphorylation of Flk-1, which
initially occurs partly in lipid rafts (Oshikawa et al., 2012;
Xiao et al., 2007). These reports suggest the possibility
that the S1P receptor could transactivate the Flk-1 and
stimulate G1-S transition in mouse ES cells. In the present
study, the data demonstrated that the binding of S1P to its
receptor (S1P1 and S1P3) recruited β-arrestin and sequen-
tially activated c-Src. However, VEGF-A164 did not affect
the β-arrestin recruitment to the S1P receptor, thereby
suggesting that the S1P-induced activation of β-arrestin and
c-Src is regulated by S1P1/3 dependent-manner. After S1P
stimulation, Flk-1 expression in the lipid raft fraction was
increased, which was blocked by lipid raft disruption. To
clarify the complex formation between S1P receptor and
Flk-1, we carried out co-immunoprecipitation and in situ
PLA, and these results revealed that S1P increased interac-
tion of S1P1 and S1P3 with Flk-1. Next, we examined the
increment in Flk-1 phosphorylation in response to S1P. In
experiments to examine the increment in Flk-1 phosphory-
lation in response to S1P, the S1P-elicited activation of
β-arrestin and c-Src is important for Flk-1 activation. These
data were supported by previous reports that the GPCR
activation caused an increase in the assembly of a protein
complex containing activated β-arrestin, c-Src, and the
receptor (Luttrell and Lefkowitz, 2002). This binding of c-Src
and β-arrestin is mediated in part by an interaction between
the c-Src homology (SH) 3 domain of the kinase and proline-
rich PXXP motifs in the β-arrestin (McDonald et al., 2000).
Previously, it has been reported that S1P has no effect on
secretion of VEGF in BAECs (Tanimoto et al., 2002). How-
ever, a more recent study showed that S1P stimulates VEGF
synthesis and secretion in epithelial cells (Sun et al., 2010),
thereby suggesting the cell type-specific effect of S1P
on VEGF production. In the present study, S1P elicited
VEGF production/secretion and both S1P and VEGF-A164
stimulated Flk-1 activation. This suggests the possibilities
that the S1P stimulates ES cell proliferation through direct
crosstalk between S1P receptors and Flk-1 and/or S1P-
induced production/secretion of VEGF activates Flk-1 as
a ligand in an autocrine/paracrine manner. Interestingly,
S1P-induced Flk-1 phosphorylation occurred in less time than
VEGF synthesis in response to S1P. Furthermore, VEGFR2
kinase inhibitor (SU1498) inhibited the S1P-induced pro-
liferation of mouse ES cells, but VEGF-A164 neutralizing
antibodies and VEGF specific siRNA partially blocked. These
results imply that S1P-induced Flk-1 activation occurred
through both a VEGF-dependent and a VEGF-independent
manner. To our knowledge, our observations are the first
to provide information concerning the role of S1P and its
receptors in terms of regulating ES cell proliferation through
the interaction with Flk-1.
S1P has an anti-apoptotic and proliferative effect in ES
cells and these S1P functions are contingent on the
activation of MAPKs (Wong et al., 2007). Previously, it has
been reported that S1P stimulates ERK, p38, or JNK phos-
phorylation, which is involved in the regulation of pluri-
potency of human ES cells (Pitson and Pebay, 2009) and
mouse ES cells (Rodgers et al., 2009). However, in the
present study, S1P activated ERK and JNK, but not p38,
which may be explained by differences in concentration of
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on the specific cell type. In addition, VEGF has also been
shown to induce phosphorylation of MAPKs through Flk-1
(Ho and Kuo, 2007). These results suggest that the S1P
receptor and Flk-1 share common downstream molecules,
and thus, it is possible that the S1P-induced VEGF-
dependent and -independent Flk-1 activation subsequently
activates MAPKs, which mediate S1P-induced mouse ES cell
proliferation. Consistent with these reports, in the present
study, both S1P and VEGF-A164 elicited the ERK and JNK
activation, and combination treatment of S1P and VEGF-A164
synergistically increased the phosphorylation level of ERK
and JNK. S1P-induced ERK and JNK activation was blocked by
S1P1/3 or Flk-1 inhibition. However, inhibition of VEGF action
through VEGF-A164 Ab and VEGF siRNA did not affect on
S1P-induced ERK and JNK activation, thereby suggesting that
S1P-indcued ERK and JNK via S1P1/3 requires Flk-1 phosphor-
ylation in absence of VEGF. It has been reported that the
serum deprivation of mouse ES cell, which is important to
develop defined culture systems in animal product-free
conditions, induced cell cycle synchronization in G1 phase
(Zhang et al., 2005). In the present study, the S1P treatment
in absence of serum stimulates the ES cell proliferation
through cyclin D1/CDK4 (early G1 phase) and cyclin E/CDK2
(late G1 phase) expression, which are important to drive
progression through G1 past a point known as the restriction
point and S-phase entry, respectively (Sherr and Roberts,
1999). Moreover, inhibition of ERK and JNK with pharmaco-
logical inhibitors blocked S1P-induced DNA synthesis and
expression of CDK4/cyclin D1 and CDK2/cyclin E. Taken
together, our observation suggests the possible role of
S1P as a physiological regulator of the G1–S phase transition
of mouse ES cells, which will provide valuable tools for
modulating ES cell function and cell fate as well as
development of defined culture systems. This is the first
report that shows the S1P-induced increase in mouse ES cell
proliferation through Flk-1 activation and related signaling
cascade. A schematic illustration of the interrelationship
between S1P and Flk-1 is shown in Fig. 9. Although many
aspects remain entirely speculative, understanding the
mechanisms by which S1P induces Flk-1 activation and cell
proliferation will shed light on future therapeutic applica-
tions of ES cells in the regenerative medicine. In conclusion,
S1P-elicited transactivation of Flk-1 mediated by S1P1/3-
dependent β-arrestin/c-Src pathways stimulated prolifera-
tion through activation of ERK and JNK in mouse ES cells.
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